INCY - INCYTE CORP

98.07
-1.970   -2.009%

Share volume: 1,644,530
Last Updated: 03-03-2026
Business Services/Services – Research, Development, Testing Labs: -0.04%

PREVIOUS CLOSE
CHG
CHG%
$100.04
-1.97
-0.02%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
33%
Profitability 0%
Dept financing 42%
Liquidity 75%
Performance 52%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-3.16%
1 Month
-4.42%
3 Months
-2.38%
6 Months
14.78%
1 Year
40.74%
2 Year
64.22%
Key data
Stock price
$98.07
P/E Ratio 
15.07
DAY RANGE
$97.00 - $99.57
EPS 
$6.59
52 WEEK RANGE
$53.56 - $112.29
52 WEEK CHANGE
$40.48
MARKET CAP 
19.391 B
YIELD 
N/A
SHARES OUTSTANDING 
199.014 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
07-29-2025
BETA 
0.75
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,774,146
AVERAGE 30 VOLUME 
$1,935,470
Company detail
CEO: Herve Hoppenot
Region: US
Website: incyte.com
Employees: 2,320
IPO year: 1993
Issue type: Common Stock
Market: XNAS
Industry: Business Services/Services – Research, Development, Testing Labs
Sector: Services

Incyte Corporation focuses on the discovery, development, and commercialization of proprietary therapeutics. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD) It also develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Recent news